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Chronic graft-versus-host disease (cGvHD) remains a major complication of allogeneic 
hematopoietic stem cell transplantation (HSCT). A number of studies support a role 
for B cells in the pathogenesis of cGvHD. In this study, we report the presence of 
an expanded population of CD19+CD21− B cells with features of exhaustion in the 
peripheral blood of patients with cGvHD. CD21− B cells were significantly increased in 
patients with active cGvHD compared to patients without cGvHD and healthy controls 
(median 12.2 versus 2.12 versus 3%, respectively; p < 0.01). Compared with naïve 
(CD27−CD21+) and classical memory (CD27+CD21+) B cells, CD19+CD21− B cells 
in cGvHD were CD10 negative, CD27 negative and CD20hi, and exhibited features 
of exhaustion, including increased expression of multiple inhibitory receptors such as 
FCRL4, CD22, CD85J, and altered expression of chemokine and adhesion molecules 
such as CD11c, CXCR3, CCR7, and CD62L. Moreover, CD21− B  cells in cGvHD 
patients were functionally exhausted and displayed poor proliferative response and 
calcium mobilization in response to B-cell receptor triggering and CD40 ligation. Finally, 
the frequencies of circulating CD21− B cells correlated with cGvHD severity in patients 
after HSCT. Our study further characterizes B cells in chronic cGVHD and supports 
the use of CD21−CD27−CD10− B cell frequencies as a biomarker of disease severity.
Keywords: chronic graft-versus-host disease, cD19+cD21−cD27−cD10− cells, exhausted B  cells, stem cell 
transplantation, cD21– B cells correlate with cgVhD severity
inTrODUcTiOn
Chronic graft-versus-host disease (cGvHD) remains a major limiting factor to the success alloge-
neic hematopoietic stem cell transplantation (HSCT). Chronic GvHD occurs in 30–65% of HSCT 
recipients with a 5-year mortality rate of up to 30–50% (1). At present, the immunopathophysiology 
of cGVHD is not fully understood, thereby hindering the development of effective treatments. 
Traditionally, cGvHD has been approached as a T cell-mediated process and many of the current 
therapies reflect this understanding (2). However, recent clinical and preclinical studies also suggest 
a role for B cells in the pathogenesis of cGvHD (3–5).
The occurrence of cGvHD in the settings of major or minor histocompatibility antigen dispar-
ity and the identification of multiple autoantibodies imply either a direct breakdown in the B cell 
self-tolerance process or the existence of aberrant B cell responses to T cell help (6, 7). Patients with 
cGvHD have a number of abnormalities in their B cell compartment, including lower frequencies of 
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marrow B cell precursors (8–11), fewer regulatory B cells (12–14), 
a skewed immunoglobulin repertoire (9, 15), as well as signifi-
cantly fewer peripheral blood (PB) CD27+ B cells compared to 
patients without cGvHD (16–19). In addition, memory B  cells 
from patients with cGvHD are activated and in a higher metabolic 
state, with increased signaling through the AKT and extracel-
lular signal-regulated kinase pathway (20), which, in association 
with elevated plasma B  cell-activating factor (BAFF) to B-cell 
ratio, may promote the aberrant survival of autoreactive B cells 
(21, 22). In addition, higher frequencies of CD19+CD21−  
B cells have been observed in the PB of patients with cGvHD. The 
authors identified these cells as transitional B cells (16, 23), and 
associated their presence with bronchiolitis obliterans syndrome 
(BOS) (24). Moreover, CD19+CD21low B  cells frequencies 
measured on day 100 following allogeneic HCT were found to 
predict for the development of cGVHD (25).
Here, we report on the presence of an expanded population of 
CD19+CD21− B cells in patients with active cGvHD. We further 
characterize this population phenotypically and functionally and 
show similarities with the exhausted B cells described in chronic 
HIV viremia (26). These features include increased expression 
of multiple inhibitory receptors, altered expression of chemokine 
and adhesion molecules, as well as poor proliferative response 
to a variety of stimuli. These data may in part explain the inad-
equacy of the antibody response against pathogens and the state 
of immunodeficiency observed in cGVHD patients.
MaTerials anD MeThODs
inclusion criteria
All patient samples were collected after written informed con-
sent, on research protocols approved by the Institutional Review 
Boards at MD Anderson Cancer Center, Houston, TX, USA 
and the Hammersmith Hospital, London England, according to 
local policy guidelines and in accordance with the declaration of 
Helsinki.
Peripheral blood samples were obtained from 55 patients who 
had undergone allogeneic HSCT between 1998 and 2011, had no 
evidence of primary disease relapse and were 6 months or more 
post-HSCT. The cohort were selected randomly and included 
patients who underwent reduced intensity or myeloablative condi-
tioning and received bone marrow or mobilized peripheral blood 
stem cell grafts from an HLA-matched sibling or unrelated donor. 
Chronic GvHD status at the time of sample collection was classi-
fied according to documented clinical and laboratory data using 
National Institutes of Health (NIH) cGvHD consensus criteria 
and the modified Seattle criteria for limited versus extensive dis-
ease (27, 28). Patients receiving high-dose steroids (>0.75 mg/kg 
prednisone) at the time of sampling or those who had received 
rituximab for any indication were excluded.
Processing of Peripheral Blood 
Mononuclear cells (PBMc)
Peripheral blood mononuclear cells were separated from whole 
blood by density gradient centrifugation (Ficoll-Hypaque, 
Durham, NC, USA), cryopreserved in 20% DMSO in fetal calf 
serum, and stored in liquid nitrogen. Prior to each experiment, 
cells were thawed and rested overnight in RPMI 1640 media 
(Gibco, UK) supplemented with 10% fetal calf serum.
classification of B cell subsets
Multiparameter flow cytometry was employed to assess B  cell 
phenotype, using a 9-color panel of conjugated mouse antihuman 
monoclonal antibodies (mAb) specific for the following markers: 
APC-H7 CD19, FITC CD24, PE CD27, PerCP-Cy5.5 IgM, and 
v450 IgD (all from BD Pharmingen™ and BD Horizon™, UK), 
APC CD21, PE-Cy7 CD38 (eBioscience, UK), and Qdot 605 
CD10 from (Invitrogen™, USA). PBMC were stained first with 
1 µl of the viability marker LIVE/DEAD Fixable Aqua Dead cell 
stain (L_D), invitrogen™, for 30 min in the dark at room tem-
perature. Cells were then washed and incubated with the cocktail 
of mAb at titrated concentrations in PBS for a further 30 min at 
room temperature. Cells were acquired on BD LSRFortessa cell 
analyzer (BD, Bioscience, USA). Data were analyzed using FlowJo 
software (Treestar, San Carlos, CA, USA). Fluorescence minus 
one and unstained controls were used for each fluorochrome to 
set gates and define positive expression.
Using CD19, CD27, and IgM co-expression, B cell subsets were 
defined as naïve (CD19+IgM+CD27−) and classical memory 
B  cells (CD19+CD27+). The latter was further subdivided 
into IgM memory (CD19+CD27+IgM+) and class-switched 
(CD19+CD27+IgM−) memory B  cells. A second phenotypic 
definition based on expression of CD19, CD24, and CD38 was also 
employed to define transitional (CD19+CD24hiCD38hi), naïve 
(CD19+CD24+CD38+), memory (CD19+CD24hiCD38−) and 
plasmablasts (CD19+CD24−CD38hi).
expression of inhibitory and chemotaxis 
receptors on B cell subpopulations
We assessed the expression of inhibitory and trafficking recep-
tors on B cell subpopulations using multi-color flow cytometry 
using the gating strategy presented in Figure S1 in Supplementary 
Material. Conjugated mouse antihuman monoclonal mAb 
specific for the following markers were employed: FITC CD22, 
PE CD27, PE CD20, PE CD85J, PE-Cy7 CCR6, APC-H7 CD19, 
and PerCP-Cy5.5 CXCR3 all from (BD Pharmingen™, UK); PE 
FCRL4, PE-y7 CD62L, and PerCP-Cy5.5 CD11c from (BioLegend, 
San Diego, CA, USA); APC CD21 from (eBioscience, UK) and 
Qdot 605 CD10 from (Invitrogen™, USA). Cells were acquired 
on BD LSRFortessa cell analyzer (BD, Bioscience, USA) and data 
were analyzed using FlowJo software (Treestar, San Carlos, CA, 
USA). Median fluorescence intensity (MFI) was used to compare 
the expression of inhibitory and chemokine receptors in the dif-
ferent study groups.
Proliferation assay Using 
carboxyfluorescein succinimidyl  
ester (cFse)
The proliferative capacity of CD19+ B  cells was assessed by 
measuring CFSE dilution after in  vitro stimulation. In brief, 
thawed PBMC were rested overnight and stained with CFSE 
(eBioscience, UK) according to the manufacturer’s protocol. Cells 
TaBle 1 | Patient, disease, and transplant characteristics.
no cgvhD (N = 23) cgvhD (N = 32) p-Value
Age in years (range) 55 (24–66) 53 (24–68) 0.65
Time post-SCT, days (range) 543 (349–4,000) 1,107 (180–2,947) 0.007
Patient sex
Male (%) 14 (60) 22 (68) 0.54
Female (%) 9 (40) 10 (32)
Donor sex
Male (%) 19 (83) 19 (59) 0.066
Female (%) 4 (17) 13 (41)
Disease
Lymphoma and  
myeloma (%)
2 (7) 13 (41)
Acute leukemia (%) 17 (74) 13 (41)
Myelofibrosis (%) 0 (0) 2 (6)
conditioning regimen
Myeloablative  
conditioning (%)
8 (35) 6 (19) 0.18
Reduced intensity 
conditioning (%)
15 (65) 26 (81)
stem cell donor
Related (%) 7 (30) 24 (75) 0.001
Unrelated (%) 16 (70) 8 (25)
stem cell source
Bone marrow (%) 8 (36.5) 4 (13) 0.6
Peripheral blood stem  
cells (%)
14 (63.5) 29 (87)
CD34+ cells ×106/kg 4.99 (0.79–12.2) 6.25 (2.8–12.77) 0.25
Posttransplant immunosuppressive prophylaxis
CsA + MTX (%) 6 (26) 7 (22) 0.83
CsA + MTX—T cell 
antibodies (%)
6 (26) 7 (22)
Tacrolimus-MTX (%) 11 (48) 18 (46)
acute gVhD
Grade 0 (%) 13 (56) 16 (50) 0.4
Grades I–II (%) 8 (35) 11 (34)
Grades III–IV (%) 2 (9) 5 (16)
Donor lymphocyte infusion (Dli)
Received DLI (%) 5 (22) 10 (31) 0.43
Received no DLI (%) 18 (78) 22 (69)
MTX, methotrexate; CsA, cyclosporine; DLI, donor lymphocyte infusion; cGvHD, 
chronic graft-versus-host disease.
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were plated at 2 × 105 cells per well of a 96-well flat-bottom plate 
with 1 µg/ml of F(ab’) 2 Goat anti Human IgG + IgM (H + L) 
(Jackson ImmunoResearch Laboratories, USA) alone, 1  µl 
per 4 ×  105  cells of anti-CD3/28 DynaBeads (Invitrogen, Oslo, 
Norway) alone or in combination. Cells were harvested, washed, 
and stained with PerCP CD4 and APC CD19 mAbs (both from 
BD Pharmingen™, UK). CFSE is usually detected at 530/30 nm. 
Samples were acquired on FACSCalibur (BD Bioscience, Oxford, 
UK) and data were analyzed using FlowJo software (Treestar, San 
Carlos, CA, USA).
calcium Mobilization assay
Calcium mobilization assay was carried out according to 
published protocol (29). Briefly, a total of 3–5 ×  106  cells were 
suspended in dye loading buffer containing 1  µM Ca2+ and 
1  µM Mg2+ ions, supplemented with 1% BSA, 0.2% pluronic 
F-127 (Sigma-Aldrich), and 5  µM Fluo-4-acetoxymethyl ester 
(Fluo-4-AM) (Invitrogen) for 25  min at 37°C. Cells were sub-
sequently stained with anti-CD19 APC-H7, anti-CD27 PE, and 
anti-CD21 APC mAbs and resuspended at a concentration of 106  
cells/ml. Intracellular calcium in gated CD19+CD27+CD21+ 
and CD19+CD27+CD21− B cells was monitored over time by 
flow cytometry. Resulting emission was measured first for 5 min 
to establish a baseline, and subsequently, 20  µg/ml of goat F 
(ab′) 2 Goat anti Human IgG + IgM (Jackson ImmunoResearch 
Laboratories) was added and emission were obtained. Ratios of 
B-cell subsets MFI at baseline and at 120 s were calculated using 
the FlowJo software (Treestar, San Carlos, CA, USA). The ratio of 
intracellular Ca+ 2 MFI at 120 s to baseline MFI was compared 
in the CD21− and CD21+ B  cell populations using the non-
parametric paired T test.
statistical analysis
Groups were compared using either the Mann–Whitney or Chi 
square test. For multiple comparisons, the Kruskall–Wallis test 
with Dunn’s posttest was used. The association of CD21− B cells 
with cGvHD was investigated using logistic regression analysis, 
taking into account all variables from the univariate analysis with 
p-values <0.10. All statistical analyses were performed using 
GraphPad Prism version 5.04 for Windows (GraphPad Software, 
La Jolla, CA, USA) and IBM SPSS Statistics for Windows, Version 
24.0. Armonk, NY, USA. All tests were considered significant 
when the two-tailed p-values <0.05.
resUlTs
Patient characteristics
Patient characteristics are summarized in Table  1. Thirty two 
patients had “active cGvHD” (limited or extensive) at the time 
of PB collection. Twenty three patients had no history of cGvHD 
after HSCT. Seventeen patients were on low dose prednisolone 
(≤0.75 mg/kg) either alone or in combination with other immu-
nosuppressants, including mycophenolate mofetil (3/32), siroli-
mus (4/32), or tacrolimus (12/32). Two patients were receiving 
extracorporeal photopheresis. None of the “no cGvHD” patients 
were on immunosuppressive therapy at the time of PB collection. 
Median time to analysis was 543 days (180–4,225) for the cGvHD 
and 1,107 days (349–4,000) for the no cGvHD group (p = 0.007). 
We also studied 18 age-matched healthy controls (HC).
chronic gvhD is associated with 
Decreased numbers of naïve and 
Transitional and higher Frequencies  
of cD27+ Memory B cells
Consistent with previously published studies (18), patients with 
cGvHD in our study had significantly lower absolute lymphocyte 
counts than patients without cGvHD and HC (median 1,300 ver-
sus 2,050 versus 1,700 cell/μl; p = 0.008 and p = 0.01, respectively); 
Figure 1A. Total CD19+ B cell numbers were also significantly 
lower in patients with cGvHD compared to patients without 
cGvHD (median 216 versus 378 cell/μl; p = 0.002); Figure 1B. 
However, patients without cGvHD had higher CD19+ B  cells 
FigUre 1 | B cell subsets in patients with or without chronic graft-versus-host disease (cGvHD) and healthy controls (HC). Box plots, showing medians, 25th and 
75th percentiles and ranges, compare total lymphocyte count (a) and total CD19+ B cell count (B) in cGvHD patients compared to “no cGvHD” patients and HC. 
(c) Representative FACS plots demonstrating CD19+ B cell phenotype in a “no GvHD,” a cGvHD patient and a healthy control. Gated CD19+ B cells were 
examined for CD24 and CD38 expression; transitional (CD19+CD24hiCD38hi), naïve (CD19+CD24+CD38+) and memory (CD19+CD24hiCD38−) B cell subsets 
are presented. (D) Scatter plots compare the percentage of individual B cell subsets in patients with “no GvHD” (n = 23), with cGvHD (n = 32) and HC (n = 18).
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compared with HC (median 378 versus 180 cells/μl; p = 0.013), 
consistent with the previously described B cell “surge” following 
HSCT (9, 21).
Next, we employed multiparameter flow cytometry to examine 
B cell subsets in post-HSCT patients and controls. In agreement 
with previously published data (22), patients with active cGvHD 
had significantly fewer transitional (CD19+CD24hiCD38hi) 
and naïve B cells (CD19+CD24+CD38+) compared to patients 
without cGvHD (median 0.5 versus 22.3  cell/μl; p =  0.08 and 
158 versus 338  cell/μl; p =  0.03, respectively). In the setting 
of relative naive B lymphopenia, patients with cGvHD had 
proportionally higher frequencies of CD27+CD19+ B  cells 
(15.6% in active cGvHD versus 6.6% in patients without cGvHD; 
p = 0.01 and 25% in HC; p = 0.0001), Figures 1C,D. The absolute 
CD27+CD19+ B cell count in the PB of patients post-HSCT was 
significantly lower compared to HC, regardless of cGvHD status 
(data not shown).
chronic gvhD Patients have higher 
Frequencies of circulating  
cD19+cD21− B cells
We identified an expanded population of CD19+CD21− B cells 
(median 12.2, 1.3–34.9%) in the PB of patients with chronic 
GvHD. In contrast, significantly fewer CD19+CD21− B cells were 
present in the PB of patients without cGvHD (2.12, 0.67–20.1%; 
p = 0.004) and HC (3, 1.5–8.15%; p = 0.01); Figure 2A. Notably, 
the only patient without cGvHD with increased frequencies of 
CD19+CD21− B cells had evidence of EBV reactivation at the 
time of analysis.
We sought to further investigate the nature of the expanded 
CD21− B  cell population in cGvHD patients in our study. 
Although expansion of CD21− B  cells in cGvHD has been 
previously reported, the authors concluded that these cells are 
immature/transitional B cells (16). We performed a comprehen-
sive phenotypic characterization of CD19+CD21− B cells in our 
cGvHD patients based on the expression of CD24, CD38, IgM, 
IgD, CD20, CD10, and CD27. The majority of CD21− B cells in 
the PB of cGvHD patients expressed high levels of CD20, lacked 
expression of CD10, CD27, CD24, and CD38 and expressed 
lower IgD and IgM than CD21+ B cells, a profile similar to that of 
exhausted B cells described in patients with chronic HIV viremia 
(26), while only a minority displayed the phenotype of transitional 
B  cells [defined as CD24hiCD38hiIgMhiIgD+CD10+CD27− 
(30)], Figures 2B–D.
Phenotypic characterization of 
cD19+cD21− B cells in cgvhD Patients
The phenotypic similarities between the expanded CD21− B cell 
population in cGvHD and exhausted B  cells in patients with 
chronic HIV viremia led us to seek a more precise phenotypic 
definition of CD20hiCD10−CD27−CD21− in cGvHD patients. 
Exhausted B cells in HIV are defined by the differential expression 
FigUre 2 | CD19+CD21− B cells in patients with or without chronic graft-versus-host disease (cGvHD) and healthy controls (HC). (a) FACS plots showing 
CD21− B cell frequency in a representative “no GvHD” patient, GvHD patient, and a healthy control. Chronic GvHD patients (n = 32) have significantly higher 
percentage of circulating CD21− B cells compared with “no cGvHD” patients (n = 23) and HC (n = 18). (B,c) Color-coded gating on CD19+ B cells in 
representative “no GvHD” and active cGvHD patients; (B) cGvHD patient has higher frequencies of CD21− B cells (red) compared with the “no cGvHD” 
representative patient (yellow). (c) Gated CD19+ B cells from the same examples are shown; the majority of CD21− B cells in the “no cGvHD” group (yellow)  
fall within the CD24hiCD38hi transitional B cell and CD24−CD38hi plasmablast regions. Conversely, the majority of CD21− B cells in “cGvHD” patients (Red)  
fall within the CD24−CD38− exhausted B cell and CD24−CD38hi plasmablast regions. (D) Phenotypic characterization of transitional (yellow) and exhausted 
CD21− B cells (red) compared with CD21+ B cells (black) in a patient with cGVHD.
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of an array of chemokine and inhibitory receptors (26), including 
upregulation of the inhibitory receptors Fc receptor-like protein 
4 (FCRL4), CD22, and leukocyte immunoglobulin-like receptor, 
subfamily B (CD85J), and altered expression of the chemotaxis 
receptors integrin alpha X (CD11c), CXCR3, CCR6, selectin 
L (CD62L), and CCR7 (31, 32). Accordingly, we explored the 
expression of these markers on the expanded CD21− B cell popu-
lation against naïve and classical memory B cells in 22 patients 
with active cGvHD and 10 no cGVHD patients; Figures 3A,B.
CD19+CD10−CD21−CD27− B  cells in cGvHD, Figure 
S1 in Supplementary Material, expressed significantly higher 
levels of CD22, CD85J, and FCRL4 compared with naïve 
(CD19+CD10−CD21+CD27−) and classical memory B  cells 
(CD19+CD10−CD21+CD27+); Figure 3C. Furthermore, CD21− 
B cells in these patients displayed a profile of altered trafficking 
and homing receptors, including significantly higher expression 
of CD11c and CXCR3 compared to naïve and classical memory 
B cells (p = 0.008 and p = 0.03 and p = 0.007 and p = 0.42, respec-
tively). In contrast, the homing receptors CCR7 and CD62L were 
expressed at significantly lower levels on CD21− B  cells com-
pared with both classical memory and naive B cells (p = 0.007 
and p = 0.008, respectively). Little difference was observed in the 
expression of CCR6 among the three B cell subsets; Figure 3C. 
In contrast, CD21− B cells form HSCT patient with no cGVHD 
expressed lower levels of CD22, CD62L, and CD11c compared 
with both naïve and memory B cells (p = 0.01, 0.004, and 0.02, 
respectively). We did not observe a significant difference in the 
expression of CD85J or FCRL4 between different B cell subsets 
(data not shown). Of note, there was no significant difference in 
frequencies of CD21−CD27+ activated memory B cells between 
the two posttransplant groups, Figure 3D.
Overall, these data indicate that CD21−CD10−CD27− B cells 
in cGvHD have altered homing and an inhibitory profile similar 
to that previously described for exhausted B cells in chronic viral 
infections (26, 31, 32).
B cells from cgVhD Patients exhibit 
impaired Proliferative Potential to B cell 
receptor (Bcr) and cD40-Mediated 
activation
To further investigate the hypothesis that B cells in cGvHD are 
exhausted, we compared the proliferative potential of CD19+ 
B cells in response to BCR engagement and CD40 triggering in 
FigUre 3 | Expression of inhibitory and chemokine receptors on CD19+CD21−CD27−CD10− B cells. (a) FACS plots from a representative chronic graft-versus-
host disease (cGvHD) patient show the expression of chemokine and inhibitory receptors on gated CD19+ B cells in relation to CD21. (B) Color-coded gating on 
CD27+CD21+ in B cells from a representative cGvHD patient. The expression of inhibitory and chemokine receptors on naïve (blue), classical memory (red), and 
CD21− B cells (black). (c) Inhibitory and homing receptor expression on CD21−CD27−CD10− B cells relative to naïve and classical CD27+ memory B cells.  
Plots depict individual median fluorescence intensity (MFI) values for each cell subpopulation from 22 cGvHD patients. (D) FACS plot show gating strategy on 
CD21−CD27+ activated memory B cells from a representative cGVHD patient (left). Scatter blot compare the frequency of activated memory B cells between  
the two post-transplant groups; p = ns. *Represents a p < 0.05, **p < 0.01, and ***p < 0.001.
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patients with or without GvHD and HC. CFSE-stained PBMCs 
from 10 cGvHD, 7 patients without cGvHD, and 10 HC were 
stimulated with anti-CD3/anti-CD28 beads [T  cells upregulate 
CD154 receptor (CD40L) upon stimulation, which in turn acti-
vates CD19+ B cells through CD40 triggering], anti IgM/anti IgG 
(BCR triggering), or the combination of anti-CD3/anti-CD28 
and anti IgM/anti IgG for 96 h (provides a dual mechanism of 
B cell stimulation) (33).
The B cell proliferative response to stimulation via CD40 trig-
gering alone (anti-CD3/CD28) or dual CD40 and BCR triggering 
was significantly lower in cGvHD patients compared to HC and 
patients without cGvHD patients [median percentage of divid-
ing cells (16.5 versus 70.75 versus 59%; p =  0.0009) and (30.3 
versus 79 versus 73.6%; p = 0.003), respectively], Figures 4A,B. 
We found no significant difference in the B  cell proliferative 
response to dual CD40 and BCR triggering in patients with no 
cGVHD and HC (p =  0.14 and p =  0.037). Analysis of gated 
B cell subsets, from 10 patients with cGVHD revealed that the 
CD21− B cell subset proliferated less in response to stimulation 
with CD40 only or to dual CD40 and BCR triggering than the rest 
of CD21+ B cells (naïve and memory) (median 4.4 versus 58.5% 
p = 0.001), and (median 1.9% versus 58.6, p = 0.0003), respec-
tively, Figures 4C,D, pointing to their inherently exhausted state.
These data indicate that the CD21−CD19+ B cell population 
in cGvHD exhibit proliferative deficiencies when compared with 
their CD21+ B cell counterpart and with B cells from patients 
without cGvHD or HC.
calcium Flux is impaired in exhausted 
cD21− B cells from cgvhD Patients
To investigate calcium signaling in B cell subsets in chronic GvHD, 
intracellular calcium levels were measured by flow cytometry in 
gated populations pre- and poststimulation of the IgM receptor 
in 10 patients with cGvHD and 8 HC. CD27−CD21− B  cells 
from chronic GvHD patients had a reduced Ca2+ mobilization 
FigUre 4 | Proliferation of CD19+ B cell in response to B cell receptor (BCR) triggering and CD40L ligation. Carboxyfluorescein Succinimidyl Ester (CFSE)-stained 
peripheral blood mononuclear cells from healthy donors and patients with or without chronic graft-versus-host disease (cGvHD) were stimulated, anti-CD3/CD28 
alone, or a combination of anti-BCR and anti-CD3/CD28 beads for 96 h. (a) Representative CFSE histograms comparing the proliferation of gated CD19+ B cells. 
(B) Comparison of B cell proliferation in 10 cGvHD patients, 7 no GvHD patients, and 10 healthy controls (HC). Chronic GvHD patients had the lowest proliferative 
potential in response to B cell stimulation compared with “no GvHD” patients and HC. (c) FACS plots of a representative cGvHD patient comparing the proliferation 
of CD27+ memory B cells and CD21+CD27− naïve B cells with CD21− B cells. (D) CD21− B cells proliferated significantly less than the rest of B cells (n = 8) when 
compared using non-parametric t-test p < 0.001.
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capacity compared to their CD21+ B cell counterpart (p = 0.005) 
Figures  5A–C. Interestingly, this was not the case when 
CD21−CD27− B  cells (mainly transitional B  cells) from HC 
were compared with CD21+ B cells (p = 0.147), indicating that 
reduced Ca2+ mobilization is specific to the exhausted CD21− 
B  cell population (Figure  5D). Overall, these data suggest that 
CD21− B cells from cGvHD patients are anergic to BCR-mediated 
stimulation, in keeping with their exhausted phenotype and 
reduced proliferative potential.
expansion of cD21−cD27−cD10− B cells 
correlates with cgvhD
To determine if the exhausted (CD19+CD21−CD27−CD10−) 
B  cell frequencies after HSCT were associated with cGvHD 
severity, we classified patients according to the frequency of 
CD19+CD21− CD27−CD10− B  cells using a cut-off of 4% 
(upper limit of normal) (26). There was a significant association 
between the frequencies of exhausted B  cells and the severity 
of cGvHD (Figure  6; p <  0.0001). We subsequently examined 
the association between cGvHD (none versus any) and other 
clinical variables (Table 1). Variables found to be significant at 
a p < 0.1 (CD19+CD21−CD27−CD10− frequency, underlying 
disease, stem cell source, and donor) were included in a logistic 
regression model. CD19+CD21−CD27−CD10− frequency 
>4% (OR = 158, 95% CI 10.2–2,441, p < 0.001), disease group 
(OR = 25.9, 95% CI 2–345, p = 0.04), and years from transplant 
(<2 versus >2 years) (OR = 10.6, 95% CI 1–108.9, p = 0.048) were 
found to be independently associated with cGvHD. Donor type 
was not significantly associated with cGVHD severity in any mul-
tivariate model. To account for the discrepancy in sample time 
posttransplant for patients with or without cGvHD, we carried out 
a logistic regression analysis but only for a sample days matched 
cohort (N =  38). As before, CD19+CD21−CD27−CD10− fre-
quency >4% (OR = 47.7, 95% CI 4–518, p = 0.001) and disease 
no cGvHD Mild Moderate Severe
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%
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FigUre 6 | CD21−CD27−CD10− B cells and severity of chronic graft-
versus-host disease (cGvHD). Box plot depict the severity of cGvHD 
(moderate to severe) according to CD21− B cell frequencies in 32 patients 
with cGVHD.
FigUre 5 | Exhausted B cells (CD21−CD27−) fail to mobilize calcium (Ca2+) in response to B cell receptor (BCR) triggering. (a,B) Peripheral blood mononuclear 
cells from chronic graft-versus-host disease (cGVHD) patients were loaded with the calcium dye Fluo-4AM and stained with monoclonal antibodies against CD19, 
CD21, and CD27 (n = 10). Ca2+ mobilization was assessed by flow cytometry after gating on CD21−CD27− and CD21+CD27− B cell subsets. CD21−CD27− 
B cells had an attenuated Ca2+ response compared to CD21+CD27− B cells. (c) Median fluorescence intensity (MFI) of Fluo-4AM was significantly lower in 
CD21−CD27− B cells (n = 10); p = 0.005. (D) CD21− B cells from healthy donors did not have reduced Ca2+ mobilization in response to BCR stimulation when 
compared with CD21+ B cells (n = 8; p = 0.15).
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group (OR = 18, 95% CI 1.4–226, p = 0.025) were found to be 
independently associated with cGvHD.
DiscUssiOn
In this study, we further characterize the previously described 
expanded population of CD19+CD21− B  cells in the PB of 
patients with active cGvHD and show for the first time that these 
cells bear the phenotypic signature of exhaustion (26), including 
increased expression of multiple inhibitory receptors, altered 
expression of homing receptors, a reduced proliferative potential, 
and a significant defect in calcium influx. The frequency of these 
cells was independently associated with the severity of cGvHD, 
providing evidence for cGvHD-associated B cell exhaustion.
Chronic GvHD is associated with perturbed B-cell homeostasis 
(22, 34, 35). Recent studies have reported CD19+CD21− B cells 
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as a predictive biomarker of cGVHD (25) and associated with 
a higher risk of BOS (24). The authors identified these cells 
as transitional B  cells (16, 23). Interestingly, in some patients 
with BOS, CD21− B  cells were CD38loCD10− and lacked 
CD27 co-expression. Expanded CD19+CD21− B  cells have 
also been observed in a number of conditions associated 
with chronic inflammation, including autoimmune disorders 
(36, 37), chronic infection (26, 29, 32, 38), and combined 
variable immune deficiency (39). Recent studies report the 
induction of a distinct subset of Tbet+ B cells in HIV infection 
that are maintained by chronic HIV viremia. Tbethi B cells were 
characterized by expression of immunoglobulin within both 
activated CD21−CD27+ memory cells and CD21−CD27− 
tissue-like memory B cells (40, 41). Indeed, the only patient in 
our study without cGvHD who had increased frequencies of 
CD19+CD21− B cells had evidence of EBV reactivation at the 
time of PB collection. However, to date, limited phenotypic and 
functional characterization of CD19+CD21− B cells has been 
performed in cGvHD. Low or absent CD21 expression is a char-
acteristic of a number of B cell subsets including, transitional 
B cells (CD10+CD27−), plasmablasts (CD10−CD27hiCD20−), 
activated memory B  cells (CD10−CD27+CD20+), and the 
recently characterized tissue-like memory exhausted B  cells 
(CD10−CD21−CD27−) (26). Transitional B  cells are defined 
by high expression of CD24 and CD38, expression of CD10 and 
absence of CD27 (30, 42, 43). Based on this definition, we show 
that CD19−CD21− B cells in our cGvHD patients are not tran-
sitional B  cells and, instead, display a phenotype reminiscent 
of tissue-like exhausted memory B  cells. These data support 
previous reports that transitional B  cells are not increased in 
cGvHD (8, 19).
The CD19/CD21 complex is an essential B-cell coreceptor that 
functions synergistically to enhance signaling through the BCR 
in response to T cell-dependent stimulation (44, 45). In addition 
to its important role in the regulation of mature B cell activation, 
CD21 is also involved in germinal center formation and regulation 
of programmed death of anergic cells with low antigenic affinities 
(44, 45). Therefore, downregulation of CD21 on PB B cells is likely 
to result in impairment in normal B-cell functions such as activa-
tion of naïve B cells, germinal B cell survival, and persistence of 
B-cell memory. In addition, downregulation of CD21 is likely to 
raise the activation threshold of B cells and contribute to anergy.
To further characterize the PB-derived CD19+CD21− B cells 
in cGvHD, we used multi-parameter flow cytometry to assess 
the expression of a panel of surface markers. The majority of 
CD19+CD21− B cells in the PB of cGvHD patients expressed high 
levels of CD20 and low levels of CD27 and CD10. Furthermore, 
the expanded CD19+CD21−CD20hiCD27−CD10− B  cell 
population in cGvHD patients expressed relatively high levels of 
the inhibitory receptors CD22, CD85J, and FCRL4. These cells 
exhibited an altered profile of chemotaxis receptors, including 
higher expression of CD11c and CXCR3, which may contribute 
to their preferential localization to inflammatory sites, and lower 
levels of CCR7 and CD62L (l-selectin), homing receptors that 
facilitate B cell migration to lymph nodes (46, 47). Such altera-
tions are similar to the signature of exhausted B cells described 
in chronic HIV viremia (26). Collectively, these data suggest 
that CD19+CD21− B cells in cGvHD are likely to preferentially 
migrate from lymphoid tissues to cGvHD inflammatory sites.
To investigate the hypothesis that CD21− B cells in cGvHD 
patients are exhausted, we evaluated their proliferative potential 
and their capacity to mobilize calcium in response to activation. 
Compared to B  cells from patients without cGvHD and HC, 
B cells from cGvHD patients, and especially the CD21− subset, 
proliferated significantly less in response to T-cell help in the form 
of CD40L alone or with BCR cross-linking. In keeping with these 
data, the CD21− B cell subset in cGvHD patients had an impaired 
calcium response to BCR stimulation compared to CD21+ B cells. 
In contrast, CD21− B cells from HC and patients without cGvHD 
patients proliferated efficiently, with no difference in their ability 
to mobilize calcium when compared with CD21+ B cells. These 
findings could be explained by the overexpression of inhibitory 
receptors by this subset of cells. Higher expression of the inhibi-
tory receptors CD22, CD85J, and FCRL4 and lower expression of 
CD21 increase the activation threshold of B cells and reduce BCR-
mediated signaling (45, 48–50). Conversely, silencing of FCRL4 
in CD19+CD21− B cells restore their response to BCR-ligation 
(51). Taken together, the increased expression of multiple inhibi-
tory receptors, altered expression of homing receptors, and their 
reduced proliferative potential suggest that this subset of B cells 
in cGvHD display an “exhausted” phenotype.
Chronic GvHD mimics autoimmune and fibrogenic condi-
tions in which B cells are constantly exposed to self antigens as 
well as pathogen-associated molecules and, therefore, are in a 
persistent state of activation (20). These inflammatory environ-
ments activate B cells in both T cell dependent and independ-
ent manners, which could in turn lead to B  cell exhaustion. A 
number of investigators have reported the presence of expanded 
populations of antigen-specific, clonal CD19+CD21−/lo B cells 
in the PB of patients with chronic viremia. These CD19+CD21lo 
B cells were anergic, with decreased proliferation and attenuated 
calcium response to BCR stimulation (26, 29, 52). It is, therefore, 
conceivable that B cell exhaustion in cGvHD is driven by chronic 
antigenic stimulation and that, in order to prevent self-destruction 
and autoimmunity, activated B cells employ mechanisms such as 
downregulation of CD21 and upregulation of inhibitory receptors 
to dampen BCR-mediated activation. There is some evidence that 
B cell exhaustion in chronic HIV viremia might be antigen driven 
(26). In addition, chronic non-specific T-independent activation 
of B cells induced by HIV-associated molecules such as gp-120 
in the presence of high BAFF levels has also been shown to cause 
functional exhaustion (53).
It is not clear whether exhausted CD19+CD21− B  cells in 
cGvHD are directly involved in the disease pathogenesis, or are 
a consequence of continuous activation in the inflammatory 
cGvHD environment or alternatively, develop as a result of 
impaired B  cell reconstitution. Without better tools to analyze 
antigen-specific B cells at the single-cell level, and a better under-
standing of antigens involved in the B cell-driven immune process 
in cGvHD, many of the concepts regarding the mechanisms of 
B cell exhaustion in cGvHD remain speculative.
A recent study reported that downregulating the expression 
of inhibitory receptors on exhausted CD21− B cells using RNAi 
technology can effectively reverse B  cell exhaustion in HIV 
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and improve immunity against pathogenic organisms (51). It is 
tempting to suggest that downregulating inhibitory receptors on 
CD19+CD21− exhausted B cells in cGvHD may also improve their 
effector function and at least partially reverse the state of immune 
impairment seen in these patients. Alternatively, if CD21− B cells 
are in fact antigen-specific and directly involved in the pathogen-
esis of GvHD, reversing their state of anergy may have deleterious 
consequences on disease severity. The observation by our group 
and others of higher frequencies of CD19+CD21− B cells in the PB 
of patients with more severe active cGvHD (16) supports a causal 
relationship between this unusually expanded subset of B  cells 
and cGvHD. Furthermore, it is possible that chronic antigenic 
stimulation or T cell-independent B cell activation in the presence 
of elevated BAFF levels may contribute to B cell exhaustion (53).
To summarize, we report the presence of an expanded 
population of exhausted CD19+CD21−CD27−CD10− B  cells 
in patients with active cGvHD. Evidence for B  cell exhaustion 
included increased expression of multiple inhibitory receptors, 
altered expression of homing receptors, and a reduced prolifera-
tive potential. These data provide a possible explanation for the 
inadequacy of the antibody response against pathogens and 
the state of immunodeficiency observed in cGvHD (54). We 
conclude that CD19+CD21−CD27−CD10− B cells may serve as 
a potential biomarker to assess the severity of cGvHD and may 
provide a potential target for therapy.
eThics sTaTeMenT
All patient samples were collected after written informed consent, 
according to local policy guidelines and in accordance with the 
declaration of Helsinki.
aUThOr cOnTriBUTiOns
AK performed experiments, participated in the design and 
interpretation of the analysis, and wrote the manuscript. AA, 
RF, CS, KK, and EG performed experiments, participated in 
interpretation of the analysis, and commented on the manu-
script. AMA, MM, HS, NC, RM, JFA, RC, and ES provided 
advice on experiments and data analysis and commented on 
the manuscript. DM and RS commented on the manuscript and 
performed statistical analysis. KR designed and directed the 
study and wrote the manuscript.
acKnOWleDgMenTs
The authors acknowledge the support of the National Institute 
for Health Research (NIHR) Biomedical Research Center (BRC). 
This work was supported by Leuka Fund.
FUnDing
This work was funded in part by CLL Moonshot. The flow stud-
ies were performed in the Flow Cytometry and Cellular Imaging 
Facility, which is supported in part by the National Institutes of 
Health through M. D. Anderson’s Cancer Center Support Grant 
CA016672.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://www.frontiersin.org/articles/10.3389/fimmu.2017.01937/
full#supplementary-material.
reFerences
1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease 
biology and therapy. Nat Rev Immunol (2012) 12(6):443–58. doi:10.1038/ 
nri3212 
2. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease 
in 2011. Curr Opin Hematol (2011) 18(6):414–20. doi:10.1097/MOH. 
0b013e32834ba87d 
3. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. 
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric 
monoclonal antibody. Biol Blood Marrow Transplant (2003) 9(8):505–11. 
doi:10.1016/S1083-8791(03)00216-7 
4. Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, et  al.  
Donor B-cell alloantibody deposition and germinal center formation are 
required for the development of murine chronic GVHD and bronchiolitis 
obliterans. Blood (2012) 119(6):1570–80. doi:10.1182/blood-2011-07-364414 
5. Young JS, Wu T, Chen Y, Zhao D, Liu H, Yi T, et al. Donor B cells in trans-
plants augment clonal expansion and survival of pathogenic CD4+ T  cells 
that mediate autoimmune-like chronic graft-versus-host disease. J Immunol 
(2012) 189(1):222–33. doi:10.4049/jimmunol.1200677 
6. Glas AM, van Montfort EH, Storek J, Green EG, Drissen RP, Bechtold VJ, 
et  al. B-cell-autonomous somatic mutation deficit following bone marrow 
transplant. Blood (2000) 96(3):1064–9. 
7. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-
versus-host disease. Haematologica (2008) 93(11):1702–11. doi:10.3324/
haematol.13311 
8. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconsti-
tution after human bone marrow transplantation: recapitulation of ontogeny? 
Bone Marrow Transplant (1993) 12(4):387–98. 
9. Storek J, Witherspoon RP, Storb R. Reconstitution of membrane IgD(-) 
(mIgD(-)) B cells after marrow transplantation lags behind the reconstitution 
of mIgD(+) B cells. Blood (1997) 89(1):350–1. 
10. Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing 
B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 
(2001) 98(2):489–91. doi:10.1182/blood.V98.2.489 
11. Sanchez-Garcia J, Serrano J, Gomez P, Martinez F, Martin C, Roman-Gomez J, 
et al. The impact of acute and chronic graft-versus-host disease on normal and 
malignant B-lymphoid precursors after allogeneic stem cell transplantation for 
B-lineage acute lymphoblastic leukemia. Haematologica (2006) 91(3):340–7. 
12. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, et  al. 
Regulatory B  cells are enriched within the IgM memory and transitional 
subsets in healthy donors but are deficient in chronic GVHD. Blood (2014) 
124(13):2034–45. doi:10.1182/blood-2014-04-571125 
13. de Masson A, Bouaziz JD, Le Buanec H, Robin M, O’Meara A, Parquet N, 
et  al. CD24(hi)CD27(+) and plasmablast-like regulatory B  cells in human 
chronic graft-versus-host disease. Blood (2015) 125(11):1830–9. doi:10.1182/
blood-2014-09-599159 
14. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, et al. IL-
10+ regulatory B cells are enriched in cord blood and may protect against 
cGVHD after cord blood transplantation. Blood (2016) 128(10):1346–61. 
doi:10.1182/blood-2016-01-695122 
15. Avanzini MA, Locatelli F, Dos Santos C, Maccario R, Lenta E, Oliveri M, 
et  al. B lymphocyte reconstitution after hematopoietic stem cell transplan-
tation: functional immaturity and slow recovery of memory CD27+ B cells. 
Exp Hematol (2005) 33(4):480–6. doi:10.1016/j.exphem.2005.01.005 
16. Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K, 
et al. Elevated numbers of immature/transitional CD21- B lymphocytes and 
deficiency of memory CD27+ B  cells identify patients with active chronic 
11
Khoder et al. cGVHD Association with B-Cell Exhaustion
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1937
graft-versus-host disease. Biol Blood Marrow Transplant (2008) 14(2):208–19. 
doi:10.1016/j.bbmt.2007.10.009 
17. D’Orsogna LJ, Wright MP, Krueger RG, McKinnon EJ, Buffery SI, Witt CS, 
et  al. Allogeneic hematopoietic stem cell transplantation recipients have 
defects of both switched and IgM memory B  cells. Biol Blood Marrow 
Transplant (2009) 15(7):795–803. doi:10.1016/j.bbmt.2008.11.024 
18. Corre E, Carmagnat M, Busson M, de Latour RP, Robin M, Ribaud P, et al. 
Long-term immune deficiency after allogeneic stem cell transplantation: 
B-cell deficiency is associated with late infections. Haematologica (2010) 
95(6):1025–9. doi:10.3324/haematol.2009.018853 
19. Hilgendorf I, Mueller-Hilke B, Kundt G, Holler E, Hoffmann P, 
Edinger M, et al. The lack of memory B cells including T cell independent 
IgM+ IgD+ memory B  cells in chronic graft-versus host disease is asso-
ciated with susceptibility to infection. Transpl Int (2012) 25(1):87–96. 
doi:10.1111/j.1432-2277.2011.01388.x 
20. Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, et al. B cells 
from patients with chronic GVHD are activated and primed for survival 
via BAFF mediated pathways. Blood (2012) 120(12):2529–36. doi:10.1182/
blood-2012-06-438911 
21. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, 
Soiffer RJ, et al. High levels of B-cell activating factor in patients with active 
chronic graft-versus-host disease. Clin Cancer Res (2007) 13(20):6107–14. 
doi:10.1158/1078-0432.CCR-07-1290 
22. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, 
et  al. Altered B-cell homeostasis and excess BAFF in human chronic 
graft-versus-host disease. Blood (2009) 113(16):3865–74. doi:10.1182/
blood-2008-09-177840 
23. Kuzmina Z, Greinix HT, Weigl R, Kormoczi U, Rottal A, Frantal S, et  al. 
Significant differences in B-cell subpopulations characterize patients with 
chronic graft-versus-host disease-associated dysgammaglobulinemia. Blood 
(2011) 117(7):2265–74. doi:10.1182/blood-2010-07-295766 
24. Kuzmina Z, Krenn K, Petkov V, Kormoczi U, Weigl R, Rottal A, et  al. 
CD19(+)CD21(low) B  cells and patients at risk for NIH-defined chronic 
graft-versus-host disease with bronchiolitis obliterans syndrome. Blood (2013) 
121(10):1886–95. doi:10.1182/blood-2012-06-435008 
25. Greinix HT, Kuzmina Z, Weigl R, Kormoczi U, Rottal A, Wolff D, et  al. 
CD19+CD21low B  cells and CD4+CD45RA+CD31+ T  cells correlate 
with first diagnosis of chronic graft-versus-host disease. Biol Blood Marrow 
Transplant (2015) 21(2):250–8. doi:10.1016/j.bbmt.2014.11.010 
26. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O’Shea MA, et al. Evidence 
for HIV-associated B  cell exhaustion in a dysfunctional memory B  cell 
compartment in HIV-infected viremic individuals. J Exp Med (2008) 
205(8):1797–805. doi:10.1084/jem.20072683 
27. Atkinson K. Clinical Bone Marrow and Blood Stem Cell Transplantation. New 
York, NY: Cambridge University Press (2003).
28. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et  al. 
National Institutes of Health consensus development project on criteria for 
clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging 
working group report. Biol Blood Marrow Transplant (2005) 11(12):945–56. 
doi:10.1016/j.bbmt.2005.09.004 
29. Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, et al. 
Expansion of functionally anergic CD21-/low marginal zone-like B  cell 
clones in hepatitis C virus infection-related autoimmunity. J Immunol (2011) 
187(12):6550–63. doi:10.4049/jimmunol.1102022 
30. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification 
and characterization of circulating human transitional B cells. Blood (2005) 
105(11):4390–8. doi:10.1182/blood-2004-11-4284 
31. Moir S, Malaspina A, Pickeral OK, Donoghue ET, Vasquez J, Miller NJ, 
et  al. Decreased survival of B  cells of HIV-viremic patients mediated by 
altered expression of receptors of the TNF superfamily. J Exp Med (2004) 
200(7):587–99. doi:10.1084/jem.20032236 
32. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al. Atypical 
memory B cells are greatly expanded in individuals living in a malaria-endemic 
area. J Immunol (2009) 183(3):2176–82. doi:10.4049/jimmunol.0901297 
33. Blair PA, Norena LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein 
MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in 
healthy individuals but are functionally impaired in systemic lupus erythe-
matosus patients. Immunity (2010) 32(1):129–40. doi:10.1016/j.immuni.2009. 
11.009 
34. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. 
The role of B  cells in the pathogenesis of graft-versus-host disease. Blood 
(2009) 114(24):4919–27. doi:10.1182/blood-2008-10-161638 
35. Sarantopoulos S, Ritz J. Aberrant B-cell homeostasis in chronic GVHD. Blood 
(2015) 125(11):1703–7. doi:10.1182/blood-2014-12-567834 
36. Wehr C, Eibel H, Masilamani M, Illges H, Schlesier M, Peter HH, et al. A new 
CD21low B cell population in the peripheral blood of patients with SLE. Clin 
Immunol (2004) 113(2):161–71. doi:10.1016/j.clim.2004.05.010 
37. Isnardi I, Ng YS, Menard L, Meyers G, Saadoun D, Srdanovic I, et  al. 
Complement receptor 2/CD21-negative human naive B cells mostly contain 
autoreactive unresponsive clones. Blood (2010) 115(24):5026–36. doi:10.1182/
blood-2009-09-243071 
38. Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et  al. 
Clonal B cells in patients with hepatitis C virus-associated mixed cryoglob-
ulinemia contain an expanded anergic CD21low B-cell subset. Blood (2011) 
117(20):5425–37. doi:10.1182/blood-2010-10-312942 
39. Rakhmanov M, Keller B, Gutenberger S, Foerster C, Hoenig M, Driessen G, 
et  al. Circulating CD21low B  cells in common variable immunodeficiency 
resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A (2009) 
106(32):13451–6. doi:10.1073/pnas.0901984106 
40. Knox JJ, Buggert M, Kardava L, Seaton KE, Eller MA, Canaday DH, et  al. 
T-bet+ B cells are induced by human viral infections and dominate the HIV 
gp140 response. JCI Insight (2017) 2(8):92943. doi:10.1172/jci.insight.92943 
41. Knox JJ, Kaplan DE, Betts MR. T-bet-expressing B cells during HIV and HCV 
infections. Cell Immunol (2017) 321:26–34. doi:10.1016/j.cellimm.2017.04.012 
42. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, et al. Novel 
human transitional B cell populations revealed by B cell depletion therapy. 
J Immunol (2009) 182(10):5982–93. doi:10.4049/jimmunol.0801859 
43. Suryani S, Fulcher DA, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, et al. 
Differential expression of CD21 identifies developmentally and functionally 
distinct subsets of human transitional B  cells. Blood (2010) 115(3):519–29. 
doi:10.1182/blood-2009-07-234799 
44. Carroll MC. CD21/CD35 in B  cell activation. Semin Immunol (1998) 
10(4):279–86. doi:10.1006/smim.1998.0120 
45. Barrington RA, Zhang M, Zhong X, Jonsson H, Holodick N, Cherukuri A, 
et  al. CD21/CD19 coreceptor signaling promotes B  cell survival during 
primary immune responses. J Immunol (2005) 175(5):2859–67. doi:10.4049/
jimmunol.175.5.2859 
46. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol (2003) 
3(10):822–9. doi:10.1038/nri1203 
47. Ehrhardt GR, Hijikata A, Kitamura H, Ohara O, Wang JY, Cooper MD. 
Discriminating gene expression profiles of memory B  cell subpopulations. 
J Exp Med (2008) 205(8):1807–17. doi:10.1084/jem.20072682 
48. Walker JA, Smith KG. CD22: an inhibitory enigma. Immunology (2008) 
123(3):314–25. doi:10.1111/j.1365-2567.2007.02752.x 
49. Lamar DL, Weyand CM, Goronzy JJ. Promoter choice and translational 
repression determine cell type-specific cell surface density of the inhibitory 
receptor CD85j expressed on different hematopoietic lineages. Blood (2010) 
115(16):3278–86. doi:10.1182/blood-2009-09-243493 
50. Sohn HW, Krueger PD, Davis RS, Pierce SK. FcRL4 acts as an adaptive to 
innate molecular switch dampening BCR signaling and enhancing TLR 
signaling. Blood (2011) 118(24):6332–41. doi:10.1182/blood-2011-05- 
353102 
51. Kardava L, Moir S, Wang W, Ho J, Buckner CM, Posada JG, et al. Attenuation 
of HIV-associated human B  cell exhaustion by siRNA downregulation 
of inhibitory receptors. J Clin Invest (2011) 121(7):2614–24. doi:10.1172/
JCI45685 
52. Charles ED, Green RM, Marukian S, Talal AH, Lake-Bakaar GV, 
Jacobson IM, et al. Clonal expansion of immunoglobulin M+CD27+ B cells 
in HCV-associated mixed cryoglobulinemia. Blood (2008) 111(3):1344–56. 
doi:10.1182/blood-2007-07-101717 
53. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, Knowles DM, et  al. HIV-1 
envelope triggers polyclonal Ig class switch recombination through a 
CD40-independent mechanism involving BAFF and C-type lectin receptors. 
J Immunol (2006) 176(7):3931–41. doi:10.4049/jimmunol.176.7.3931 
12
Khoder et al. cGVHD Association with B-Cell Exhaustion
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 1937
54. Hilgendorf I, Freund M, Jilg W, Einsele H, Gea-Banacloche J, Greinix H, et al. 
Vaccination of allogeneic haematopoietic stem cell transplant recipients: report 
from the international consensus conference on clinical practice in chronic 
GVHD. Vaccine (2011) 29(16):2825–33. doi:10.1016/j.vaccine.2011.02.018 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Khoder, Alsuliman, Basar, Sobieski, Kondo, Alousi, Szydlo, 
Muftuoglu, Shaim, Apperley, Gokdemir, Cooper, Mehta, Marin, Champlin, Shpall 
and Rezvani. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
